Combination and Rotational Therapy in Androgenetic Alopecia

This review discusses potential strategies for rejuvenating miniaturizing hair follicles in androgenic alopecia but reports no new clinical results; it explores the idea of using DHT-resistant follicle preservation for long-term hair maintenance.

This review indicates that low-level laser therapy may stimulate hair growth in both men and women with androgenetic alopecia, showing similar efficacy to minoxidil in some studies, but requires more robust evidence.

This expert group provided recommendations for preparing and using platelet-rich plasma in treating androgenetic alopecia, suggesting a manual double-spin method and specific dosing, although further studies on injectable platelet-rich fibrin are needed.

This review indicates that most studies reported positive effects of platelet-rich plasma injections for treating androgenic alopecia, with no major side effects, suggesting it may be a safe alternative to Minoxidil and Finasteride.

This review discusses post-finasteride syndrome, characterized by persistent symptoms despite discontinuation, and concludes that its existence cannot be confirmed; individualized assessment is advisable for those with a history of depression, sexual dysfunction, or infertility.

This review discusses the evidence for post-finasteride syndrome as a condition potentially induced by finasteride and dutasteride, associating them with sexual dysfunction, depression, anxiety, and suicidal ideation in a subset of men, and reports no new clinical results.

This review article provides an updated overview of the pharmacology, mechanism of action, clinical efficacy, and adverse events associated with topical minoxidil, a widely used treatment for androgenetic alopecia and other hair loss conditions, while noting that its exact mechanism is still not fully understood.

This meta-analysis found that dutasteride was more effective than finasteride in increasing hair count and improving photographic assessments for men with androgenetic alopecia, while both drugs had similar rates of sexual dysfunction-related adverse effects.

This article discusses post-finasteride syndrome as a distinct syndrome related to prolonged use of 5α-steroid reductase inhibitors, noting persistent side effects even after discontinuation and no new research results are reported.

In a 24-week randomized trial, this study found that the RAMACAP laser helmet significantly increased hair density and diameter in androgenetic alopecia patients compared to a sham device, although limitations included a small sample size and potential issues with the control used.

This study found that finasteride 1 mg improved hair growth in 85.7% of Korean men with androgenetic alopecia over five years, with varying effectiveness depending on the type of hair loss.

This review discusses the use of platelet-rich plasma as a treatment for androgenetic alopecia and highlights the need for standardized protocols, reporting no new clinical results.

This review finds preliminary evidence suggesting that topical finasteride may significantly reduce hair loss and increase hair counts in treating androgenetic alopecia, with a promising safety profile.

In this study, adding low-level light therapy to minoxidil significantly improved hair regrowth and patient satisfaction in treating androgenetic alopecia compared to minoxidil alone.

This review discusses platelet-rich plasma treatment for androgenic alopecia, summarizing current understanding of the disease and the need for standardized clinical trials, but it reports no new results.

This guideline review by the European Dermatology Forum evaluates current treatments for androgenetic alopecia but reports no new research findings, aiming to assist dermatologists in selecting safe and effective therapies.

This study found that 5% activated platelet-rich plasma significantly improved cell proliferation and hair-inductive ability of dermal papilla cells in vitro, and promoted hair follicle formation in mice.

This study found that a 15% topical minoxidil solution improved hair regrowth in 60% of women with female pattern hair loss who did not respond to the standard 5% solution, without adverse effects.

In this review, the authors discuss the pharmacology of dutasteride and compare its efficacy to finasteride for treating androgenetic alopecia, highlighting dutasteride's effectiveness demonstrated in several clinical trials.

This study found that longer exposure to 5α-reductase inhibitors significantly increased the risk of persistent erectile dysfunction, especially in younger men exposed to finasteride.

This study found that platelet-rich plasma significantly increased hair density and anagen hair proportions in androgenetic alopecia patients, suggesting potential as an adjuvant therapy.

This review discusses the use of finasteride for androgenetic alopecia and highlights that while it is considered safe, there is concern regarding its sexual side effects, which reverse upon discontinuation.

In this study, topical minoxidil 5% was found to be just as effective as a combination treatment with minoxidil, azelaic acid, and tretinoin for treating androgenetic alopecia.

This study found that platelet-rich plasma injections significantly increased hair count and density in patients with male pattern hair loss without major side effects, suggesting it may be a safe and effective treatment option.

This study presents a new model for androgenetic alopecia progression, explaining diffuse hair loss in women through 3D reconstructions of the arrector pili muscle and its relationship with the hair follicle stem cell niche.

In this study, long-term finasteride treatment improved androgenetic alopecia in Japanese men, with younger age and less advanced disease at treatment start predicting better efficacy.

This review concluded that oral finasteride for men and topical minoxidil for both genders have the most evidence supporting their effectiveness and safety for treating androgenetic alopecia.

This study found that in androgenic alopecia, the arrector pili muscle degenerates and is replaced by fat, unlike in normal skin or telogen effluvium.

This study found that low-level laser treatment with the HairMax Lasercomb significantly increased terminal hair density in both men and women with pattern hair loss, with no serious adverse events reported.

This study found that PRP injections may improve hair density and reduce hair loss in patients with androgenetic alopecia without significant side effects, but further research is needed to confirm efficacy.

This study reviews the significant prevalence of organic etiologies, especially vascular causes, in erectile dysfunction among men under 40 and emphasizes thorough evaluation and consideration of treatment options like exercise and PDE-5 inhibitors.

In this study using a mouse model, the researchers found that platelet-rich plasma significantly increased the number of newly formed hair follicles and decreased the time for hair formation compared to no treatment.

This study found that low level laser therapy at 655 nm significantly increased hair counts in males with androgenetic alopecia.

This review discusses the potential mechanisms and evidence supporting low-level laser therapy for stimulating hair growth in men and women, while noting its safety and effectiveness but needing further study on specific parameters.

This study found that low-level light therapy significantly increased hair density and diameter in androgenetic alopecia patients compared to a sham device, suggesting it could be an effective treatment option.

In this study, 96% of men with persistent sexual side effects from finasteride reported continued dysfunction after discontinuation, suggesting these effects may endure long-term.

This review describes minoxidil's hair regrowth mechanism and discusses dermatological applications, but reports no new clinical results, emphasizing the need for regular use and addressing allergic reactions.

This review discusses the applications of low level laser therapy (LLLT) in wound healing, pain reduction, and treating various conditions, but reports no new clinical results; the authors highlight the need for randomized controlled trials for serious diseases.

This study found that finasteride 1 mg was effective in improving androgenetic alopecia over 10 years in men, particularly those older than 30, with some reporting beneficial results even after 5 years.

This study found that 94% of healthy men reported low libido and 92% reported erectile dysfunction as persistent sexual side effects after using finasteride for male pattern hair loss, with these effects lasting on average 40 months post-discontinuation.

This study found that the HairMax LaserComb® significantly increased hair density and was safe and well tolerated for treating androgenetic alopecia in men compared to a sham device.

In this study, treatment with finasteride 1 mg/day for five years significantly reduced the likelihood of further visible hair loss in men with androgenetic alopecia compared to placebo.

This study concluded that a combined once-daily solution of 5% minoxidil and 0.01% tretinoin is as effective and safe as the conventional twice-daily 5% minoxidil application for treating androgenetic alopecia in men.

This study found that dutasteride effectively improves symptoms of benign prostatic hyperplasia, showing benefits in urinary flow and quality of life, with only modestly elevated sexual side effects compared to placebo.

This study found that an intermittent low-dose regimen of finasteride (2.5 mg every 3 days) effectively reduced hirsutism scores in women with idiopathic hirsutism or polycystic ovary syndrome, with fewer side effects than continuous daily administration.

This study found that dutasteride more effectively reduced serum dihydrotestosterone levels than finasteride in patients with benign prostatic hyperplasia.

This study suggests that miniaturization in pattern hair loss may occur abruptly and can be reversed with treatment, as supported by histologic evidence in finasteride-responsive patients.

In this study, men using 2% and 5% minoxidil solutions experienced a significant increase in hair weight for 96 weeks compared to placebo, with effects diminishing after treatment cessation.

In this study, finasteride doses as low as 0.2 mg per day significantly reduced both scalp skin and serum DHT levels in men with androgenetic alopecia.

This study found that oral finasteride 1 mg/day promotes hair growth and prevents further hair loss in a significant proportion of men with male pattern hair loss over two years.

This article reviews the pathogenesis, genetic basis, and recent treatment breakthroughs for androgenetic alopecia but reports no new clinical findings.

This study found that minoxidil absorption through the skin increased with longer contact times, reaching over 75% of the maximum absorption within four hours.

Minoxidil treatment increased hair growth for up to 5 years, requiring twice daily application.

This study found that finasteride significantly suppresses serum dihydrotestosterone levels at all tested doses in normal male volunteers without significant adverse effects.

In this study, minoxidil treatment was associated with an increase in nonvellus scalp hairs, but this effect was not sustained once the treatment was stopped.

This study observed that 2% minoxidil solution was at least as effective as 3% for increasing hair growth and stabilizing bald areas in men with male pattern baldness.